[Drug name]
Generic name: Latanoprost Eye Drops
English name: Latanoprost Eye Drops
[Composition]
The main ingredient of this product is latanoprost. Its chemical name is (Z)-7-[(1R, 2R, 3R, 5S) 3, 5-dihydroxy-2-[(3R)-3-hydroxy-5-phenyl-1-pentyl] cyclopentyl]-5-heptenoic acid isopropyl ester
The bacteriostatic agent of this product is benzalkonium chloride, and its labeled amount is 0.02%.
[Description]
Colorless clear liquid.
[Indications]
Reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.
[Strength]
2.5 ml: 125 µg
[Posology and Method of Administration]
Recommended adult dosage (including elderly):
One drop in the affected eye, once a day. It works best when used at night.
This product should not be used more frequently than once daily, as an increase in the frequency of administration may impair the IOP-lowering effect.
If you forget to take a dose, you should take it as usual for the next dose.
If other ocular medications are required, they should be administered at least 5 minutes apart.
As with other eye drops, the lacrimal sac at the canthus should be pressed for 1 minute after each instillation to reduce systemic absorption (occlusion of the punctum).
Children: see [Pediatric Use]
[Pharmacological Effect]
The active ingredient latanoprost is an analogue of prostatin F2α. As a selective prostaglandin FP receptor agonist, it can lower IOP by increasing aqueous humor outflow. In humans, IOP reduction begins approximately 3 to 4 hours after administration and reaches a maximum effect at 8 to 12 hours. The IOP lowering effect is maintained for at least 24 hours. Both animal and human studies have shown that the main mechanism of action of the drug is to increase uveoscleral accessory pathway outflow of aqueous humor, although a slight increase in the facilitation of outflow of aqueous humor (reduced drainage resistance) has also been reported in humans.
Major clinical studies have demonstrated the efficacy of monotherapy with this product. In addition, clinical studies of drug combination have been conducted, and these studies have shown that latanoprost is effective in combination with a beta-adrenergic blocking agent (timolol). Short-term studies (1 or 2 weeks) showed additive effects of latanoprost in combination with an adrenergic agonist (dipivalyl epinephrine) and an oral carbonic anhydrase inhibitor (acetazolamide), and at least partially additive effects with a choline agonist (pilocarpine).
Clinical studies have also shown that latanoprost has no apparent effect on aqueous humor production and does not have any effect on the blood flow-aqueous humor barrier.
At clinical doses and in monkey studies, latanoprost had no or negligible effects on ocular circulation. However, mild to moderate conjunctival or scleral hyperemia may occur with topical application.
Chronic administration of latanoprost to monkeys undergoing extracapsular lens extraction did not affect retinal vascularity as determined by fluorescence angiography.
Short-term latanoprost treatment does not cause fluorescein leakage from posterior chamber intraocular lenses.
No significant pharmacologic effects of latanoprost on the cardiovascular or respiratory systems were observed at clinically therapeutic doses.
[Storage]
Refrigerate at 2-8 ℃ before unpacking, and store in tightly closed containers, protected from light.
After unpacking, it can be stored at room temperature below 25 ℃ and used up within 4 weeks.
[Package]
The eye drops are packed in a polyethylene plastic bottle and packed in a carton, 1 bottle/box.
[Shelf Life]
24 months
